Tonix Pharmaceuticals Holding Corp. (TNXP)

NASDAQ: TNXP · IEX Real-Time Price · USD
0.534
+0.001 (0.13%)
At close: Sep 30, 2022 4:00 PM
0.540
+0.006 (1.09%)
After-hours: Sep 30, 2022 7:58 PM EDT
0.13%
Market Cap 23.93M
Revenue (ttm) n/a
Net Income (ttm) -101.89M
Shares Out 44.80M
EPS (ttm) -7.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date May 17, 2022
Volume 1,354,241
Open 0.535
Previous Close 0.534
Day's Range 0.522 - 0.558
52-Week Range 0.520 - 20.160
Beta 1.63
Analysts Buy
Price Target 38.76 (+7,155.7%)
Earnings Date Nov 7, 2022

About TNXP

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand bein... [Read more...]

Industry Biotechnology
Founded 2007
CEO Seth Lederman
Employees 73
Stock Exchange NASDAQ
Ticker Symbol TNXP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for TNXP stock is "Buy." The 12-month stock price forecast is 38.76, which is an increase of 7,155.71% from the latest price.

Price Target
$38.76
(7,155.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pa...

Approximately 40% of Long COVID Patients Experience Multi-Site Pain Similar to Overlapping Chronic Pain Syndromes Fibromyalgia and ME/CFS

1 week ago - GlobeNewsWire

Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention...

TNX-1500 Treatment Prevents Organ Rejection and Preserves Function for Both Allograft and Xenograft Transplants in Animal Studies

2 weeks ago - GlobeNewsWire

Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the Internation...

CHATHAM, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced three oral presen...

3 weeks ago - GlobeNewsWire

Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVAIL Study of TNX-102 SL for the Treatment of Long COVID

Results from Planned Interim Analysis Expected First Half 2023

1 month ago - GlobeNewsWire

7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher

Monkeypox stocks, our topic for today, have had a mostly mixed performance so far in 2022. It is likely, however, that they could benefit from the similar tailwinds enjoyed by companies, such as Pfizer ...

1 month ago - InvestorPlace

Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Phase 1 Study of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and Smallpox, Expected to Initiate in First Half 2023 in Kenya; the U.S. has Declared Monkeypox a Public Health Emergency

1 month ago - GlobeNewsWire

Tonix Pharmaceuticals (TNXP) Stock Surges 15% on Patent News

Clinical-stage biotechnology firm Tonix Pharmaceuticals (NASDAQ: TNXP ) – which focuses on novel therapeutics and diagnostics – is making waves today, announcing the issuance of a patent. Specifically, ...

2 months ago - InvestorPlace

Tonix Pharmaceuticals Announces Collaboration with Kenya Medical Research Institute to Develop TNX-801 in Kenya as a ...

Phase 1 Clinical Study Expected to be Initiated in Kenya in the First Half of 2023

2 months ago - GlobeNewsWire

Tonix Pharmaceuticals Announces Appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Res...

CHATHAM, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of...

2 months ago - GlobeNewsWire

Tonix Pharmaceuticals Announces Development of TNX-601 ER, a Potential Abuse Deterrent, Extended-Release Formulation ...

Naloxone-Free Formulation of Tianeptine is an Extended-Release Tablet that Includes Inactive Ingredients and Compression Properties Designed to Confer Abuse Deterrence

2 months ago - GlobeNewsWire

Tonix Pharmaceuticals Announces Presentation at the World Orphan Drug Congress USA

CHATHAM, N.J., July 06, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will present at...

2 months ago - GlobeNewsWire

Tonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred Stock

CHATHAM, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities pur...

3 months ago - GlobeNewsWire

Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Program...

The ADC is Expected to Accelerate Clinical-Scale Manufacturing of Live Virus Vaccines, Including Vaccines for Monkeypox, Smallpox and COVID-19

3 months ago - GlobeNewsWire

Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention...

Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hos...

3 months ago - GlobeNewsWire

7 Monkeypox Stocks That May Take Off in Q2

SIGA Technologies (SIGA) may lead on the list of monkeypox stocks that could soar, but Bavarian Nordic seems to be leading the sales race. The post 7 Monkeypox Stocks That May Take Off in Q2 appeared fi...

Other symbols: ABTBVNRYCMRXEBSINOSIGA
3 months ago - InvestorPlace

Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadi...

Oral Presentation Describes Activity of Wnt/β-Catenin Signaling Pathway Inhibitors Against SARS-CoV-2 in Cell Culture and in an Animal Model Oral Presentation Describes Activity of Wnt/β-Catenin Signali...

3 months ago - GlobeNewsWire

Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of ...

Poster Presentation Includes Preclinical Data from Tonix's Program to Develop a Vaccine for Monkeypox and Smallpox Poster Presentation Includes Preclinical Data from Tonix's Program to Develop a Vaccine...

3 months ago - GlobeNewsWire

Tonix Pharmaceuticals Announces Presentation at the 2022 BIO International Convention

CHATHAM, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman...

3 months ago - GlobeNewsWire

Tonix Pharmaceuticals jumps 25%, and here is why

Tonix Pharmaceuticals Corp (NASDAQ: TNXP) was up 25% after announcing that the US Patent and Trademark Office gave it a US Patent No. 11,342,896 on May 31, 2022.

3 months ago - Invezz

What's Going On With Tonix Pharmaceuticals Shares Today?

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower by 6.03% to $2.96 during Thursday's pre-market session. The company announced Thursday that it has regained compliance with the...

4 months ago - Benzinga

Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

CHATHAM, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that it has regained compliance with the ...

4 months ago - GlobeNewsWire

Why Is Tonix Pharmaceuticals (TNXP) Stock Up 30% Today?

TNXP stock is rallying because Tonix received a patent for its potential monkeypox vaccine and broader Recombinant Pox Virus platform. The post Why Is Tonix Pharmaceuticals (TNXP) Stock Up 30% Today?

4 months ago - InvestorPlace

Why Tonix Pharmaceuticals Stock Is Soaring

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading higher Wednesday after the company announced that the United States Patent and Trademark Office issued a patent to Tonix titled, "Syn...

4 months ago - Benzinga

Tonix's stock jumps 43% on patent for experimental pox vaccines

Shares of Tonix Pharmaceuticals Holding Corp. TNXP, +8.93% gained 43.8% in premarket trading on Wednesday after the company said the U.S. Patent and Trademark Office issued a patent to the company's pox...

4 months ago - Market Watch